Results 101 to 110 of about 1,723 (196)

The interplay of poorly soluble drugs in dissolution from amorphous solid dispersions

International Journal of Pharmaceutics: X
In recent years, the application of fixed dose combinations of antiretroviral drugs in HIV therapy has been established. Despite numerous therapeutic benefits, this approach poses several challenges for the formulation development especially when poorly ...
Marcel Kokott, Jörg Breitkreutz, Raphael Wiedey   +2 more
doaj   +1 more source

BIORELEVANT DISSOLUTION MEDIA: ITS CURRENT STATUS AND FUTUTRE PERSPECTIVES

The landscape of dissolution media has been dynamically evolving with newer drugs entering the market among which most of them are either BCS class II or BCS class IV drugs exhibiting poor solubility.
Mehta, Tejal, Hariharan, Kartik, Panchal, Maulik   +2 more
core  

Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling

, 2009
Since the rate-determining step to the intestinal absorption of poorly soluble drugs is the dissolution in the gastrointestinal (GI) tract, postprandial changes in GI physiology, in addition to any specific interactions between drug and food, are ...
Mao, Y., Janssen, N., Vertzoni, M., Reppas, C., Shono, Y., Dressman, J.B., Kesisoglou, F., Jantratid, E.   +7 more
core  

Evaluating the fed state impact on drug solubility and absorption : a biorelevant in vitro approach

Biopharmaceutics, which studies the relationship between a drug's physical, chemical, biological, and pharmacological properties and its dosage form, is essential for studying and optimising oral formulations.
Silva, Maria Inês
core   +1 more source

Development of a biorelevant methodology for drug release in the mouth [PDF]

, 2020
The oral route is the most popular and convenient route for drug administration. There are a growing number of alternative solid oral dosage forms that have been developed for more specialised drug delivery compared to monolithic solid oral dosage forms.
Ali, Joseph
core  

A Comprehensive Study of Solid Lipid Microparticles (SLMs) Behavior in Biorelevant Dissolution Media

, 2013
The aim of this research was to study the release performance of solid lipid microparticles (SLMs) in various biorelevant dissolution media simulating the conditions of the gastric tract and the proximal human intestine.
DI SABATINO, MARCELLO, PASSERINI, NADIA, ALBERTINI, BEATRICE   +2 more
core  

Dissolution Rate and Apparent Solubility of Poorly Soluble Drugs in Biorelevant Dissolution Media

, 2016
A series of poorly soluble BCS class II compounds with “grease ball” characteristics were assessed for solubility and dissolution rate in biorelevant dissolution media (BDM) with the purpose of investigating which molecular structures gain most in ...
Na Sun (535425), Christel A. S. Bergström (1294281), Oksana Tsinman (2261866), Konstantin Tsinman (2261869), Jonas H. Fagerberg (651881), Alex Avdeef (2261872)   +5 more
core   +1 more source

Use of biorelevant dissolution media as a predictive method oral bioavailability

, 2019
Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Rio de Janeiro, RJ, Brasil.A dissolução é uma etapa fundamental para a absorção dos fármacos administradospela via oral.
Lemos, Hemilliano de
core   +1 more source

Toward biorelevant dissolution : application of a biphasic dissolution model as a discriminating tool for HPMC matrices containing a model BCS class II drug

, 2012
The potential of a biphasic dissolution system to assist with the analysis of controlled-release (CR), Biopharmaceutics Classification System (BCS) Class II pharmaceutical products has been investigated.
Cooper, Brett, Mann, J. C., Pygall, S. R., Phillips, Daniel J.   +3 more
core  

Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products. [PDF]

Mol Pharm, 2019
Hassoun M, Malmlöf M, Scheibelhofer O, Kumar A, Bansal S, Selg E, Nowenwik M, Gerde P, Radivojev S, Paudel A, Arora S, Forbes B.   +11 more
europepmc   +1 more source